Prostate and prostate cancer
Prostate is an exocrine gland, located below urinary bladder and in front of the rectum. In healthy males it weights 7-16 g, depending on the BMI. The gland is surrounded by (anterior) fibromuscular zone (stroma) that is continuous with the bladder and sheathed in the muscles of pelvic floor. Sperm from the testes flows via vasa deferentia to prostate. Prostate and seminal vesicles, located behind the prostate, excrete fluids that along with spermatozoa form the semen. The urethra runs from bladder through the prostate to the penis. The excretory ducts of each seminal gland unites with vas deference, forming two ejaculatory ducts, which pass through the prostate gland and drain into the urethra. Peripheral zone of prostate gland surrounds the distal urethra, and transition zone surrounds the proximal urethra. Transition zone grows throughout the life, causing benign prostatic enlargement (hyperplasia). The central zone surrounds the ejaculatory ducts; cancers in this region are not common, but aggressive and can invade the seminal vesicles.
Women have histologically similar organ, paraurethral gland, or Skene’s gland (Flamini et al., 2002).
Prostate cells contain ∼10-fold concentration of zinc in their mitochondria, compared to other cells. Zn2+ inhibits oxidation of citrate in TCA cycle, and citrate is produced and excreted into prostatic fluid in high concentration. In prostate cancer, cancer cells start to consume citrate, reducing citrate levels up to 40-fold (Iacobazzi & Infantino, 2014).
Prostate cancer is a common cancer in men, but remains to be difficult to treat and locate. Circulating prostate-specific antigen (PSA) levels are used for screening of prostate cancer, but PSA levels can be increased for other reasons, such as prostate inflammation. Biochemical recurrence (BCR) occurs in ∼20-40% of patients. The growth and survival of cancer cells is typically dependent on androgen receptors. Treatment includes androgen-deprivation therapy (ADT), but after 2-8 years of ADT, circulating PSA increases again, indicating metastatic castration-resistant (androgen-independent) prostate cancer (SchwarzenBoeck et al., 2017). Cancer cells may become hypersensitive to androgens, or develop other mechanisms to sustain growth. The main site of metastases is bone, representing >90% of patients with metastatic disease.
Multiparametric MRI (mpMRI) is important tool in detecting and local staging of prostate cancer, but its reported accuracy, sensitivity, and specificity are very variable (Fütterer et al., 2015).
[18F]FDG has poor sensitivity because of typically low glycolytic activity of prostate cancer and high radioactivity in the urinary bladder. Specificity is poor, too, because of high uptake in inflammation. [18F]FDG uptake is high in normal testis, but declines with age (Kosuda et al., 1997). 11C- and 18F-labelled choline, and [11C]acetate offer somewhat better specificity and sensitivity than [18F]FDG, but not as good as mpMRI (Boustani et al., 2018; Malaspina et al., 2018). Search for better PET tracers has therefore continued, but also development in PET scanners and reconstruction methods may improve the results, even with [18F]fluorocholine (Behr et al., 2018).
Tissue perfusion is typically high in aggressive prostate cancer, which may help in risk assessment. [15O]H2O PET as a quantitative and reproducible method has been used to validate relative perfusion values obtained using MRI (Muramoto et al., 2002). Kurdziel et al. (2003) followed anti-angiogenic treatment response using [15O]H2O, [11C]CO, and FDG. Input function can be derived noninvasively either using population-based curve or LV cavity curve from another scan performed just before or after the scan of the pelvic region (Tolbod et al., 2018). 82Rb can also be used to quantify perfusion in prostate cancer noninvasively (Tolbod et al., 2015).
Copper transporter 1 (CTR1) is upregulated in prostate cancer cells. Since Cu2+ is not excreted to urine, it is particularly suitable for detecting tumours in pelvic area. [64Cu]CuCl2 can be used for PET imaging of prostate cancer and its relapse (Capasso et al., 2015; Piccardo et al., 2018). [64Cu]CuCl2 has shown high uptake in prostate cancer and involved lymph nodes (Capasso et al., 2015).
The σ-receptor is being studied as a possible target for prostate cancer imaging (Yang et al., 2017).
Leucine analogue fluciclovine (anti-[18F]FACBC, Axumin®) has low renal clearance, and performs better than previous tracers (Nanni et al., 2016). In prospective studies, [18F]fluciclovine has shown equal or better performance as mpMRI (Jambor et al., 2018; Akin-Akintayo et al., 2018). Combined mpMRI or MRI and [18F]fluciclovine PET may offer additional benefits (Turkbey et al., 2014; Elschot et al., 2018).
GRP receptors are overexpressed in almost all prostate cancers, and several GRP/bombesin analogues have been developed and successfully used in imaging prostate cancer and other tumours (Sonni et al., 2017; Baratto et al., 2017).
PSMA targeting radioligands have been found to have excellent sensitivity and accuracy, even better than mpMRI (Eiber et al., 2016; Maurer et al., 2016; Bailey & Piert, 2017; Mena et al., 2018; Hicks et al., 2018). Yet, [18F]fluoride PET may detect more bone metastases than [68Ga]PSMA-11 (Uprimny et al., 2018; Zacho et al., 2018). Eiber et al (2018) have proposed a molecular imaging TNM system (miTNM) as a standardized reporting framework for PSMA-ligand PET/CT and PET/MRI. Werner et al (2018) have proposed a MI-RADS framework for targeted radiotracers with theranostic implications, including RADS classification for PSMA-targeted PET imaging (PSMA-RADS).
Cook G (ed.): PET/CT in Prostate Cancer. Springer, 2017. ISBN 978-3-319-57624-4. doi: 10.1007/978-3-319-57624-4.
Culig Z (ed.): Prostate Cancer - Methods and Protocols. Springer, 2018. doi: 10.1007/978-1-4939-7845-8.
Kim SH, Cho JY (eds.): Oncologic Imaging - Urology. Springer, 2017. doi: 10.1007/978-3-662-45218-9.
Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prost Cancer Prostatic Dis. 2018; 21: 4-21. doi: 10.1038/s41391-017-0007-8.
Polascik TJ (ed.): Imaging and Focal Therapy of Early Prostate Cancer, 2nd ed. Springer, 2017. doi: 10.1007/978-3-319-49911-6.
Updated at: 2019-04-17
Created at: 2018-01-09
Written by: Vesa Oikonen